You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: CHAPERONE THERAPEUTICS, INC. Topic: NIDCD
PROJECT SUMMARY The studies proposed here address a significant health issue the high incidence of acquired deafness from noise overstimulation that can result from recreational and workplace related activities and from service in the military Through a robust academic pharma partnership between investigators at the Kresge Hearing Research Institute with long standing interests and expertise in ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: CH3 BIOSYSTEMS, LLC Topic: 300
Project Summary Abstract The long term objective of this project is the generation of a universal drug discovery platform based on protein arginine methylation mechanisms involved in human disease The importance of protein arginine methylation in the context of human disease has become clear in the last few years with the realization that protein arginine methyltransferases and the target prot ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: MEDCHEM PARTNERS LLC Topic: NEI
7. PROJECT SUMMARY Diseases of the ocular surface are among the top reasons for visits to eye care practitioners. These conditions can severely affect eyesight and quality of life. Symptoms may include blurry vision, discomfort or pain, redness and itching, and in severe cases, blindness due to corneal scarring. Many ocular surface diseases are initiated by loss of tear film homeostasis and can be ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: CONVERGENT ENGINEERING INC Topic: NICHD
DESCRIPTION (provided by applicant): Preeclampsia, a hypertensive disorder of pregnancy, is a leading cause of maternal and neonatal morbidity and mortality around the world, responsible for approximately 76,000 maternal and 500,000 infant deaths per year.As a heterogeneous and poorly understood disorder, its pathogenesis and possible treatments are an area of active research. While the majority o ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: Tier 1 Performance Solutions, LLC Topic: DHA17B002
Approximately 70% of sentinel events in medical care are related to communication mishaps, and despite regular and frequent occurrence, an even higher percentage (80%) of severe medical errors are related to miscommunication during handoffs (i.e., the transferring of information, responsibility, and authority for patient care from one provider to another). The TiER1 team proposes to address challe ...STTR Phase I 2018 Department of DefenseDefense Health Agency
SBC: INVENUX, LLC Topic: NCCAM
DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: VASCULAR VISION PHARMACEUTICAL CO Topic: NCI
DESCRIPTION (provided by applicant): Enabling high dose regional chemotherapy with minimal systemic toxicity Abstract: The primary objective of this proposed study is to develop a filtration system that maximizes the removal (gt90%) of chemotherapeutic agents, such as doxorubicin, from blood while minimizing adverse effects of filtration on blood chemistry and hematological parameters. Vascular V ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: Simpore Inc. Topic: 400
DESCRIPTION provided by applicant The global market for nanoparticles NP in biotechnology drug development and drug delivery was estimated to be $ B for and is expected to reach more than $ B by The two most active areas of product development are NPs for drug delivery and for in vivo imaging In these applications it is often critical that he outer surfaces of NPs are functiona ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Phoenix Nest Inc. Topic: 107
DESCRIPTION provided by applicant Sanfilippo disease type B also called mucopolysaccharidosis type III or MPS III is a devastating neuro degenerative genetic disorder of childhood that is fatal There is no cure or effective treatment MPS IIIB is caused by the lack of a lysosomal enzyme called NAGLU alpha N acetylglucosaminidase that is required to degrade heparan sulfate glycosaminoglyca ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: KITWARE INC Topic: 105
Project Summary Morphometric analysis is a primary algorithmic tool to discover disease and drug related effects on brain anatomy. Neurological degeneration and disease manifest in subtle and varied changes in brain anatomy that can be non-local in nature and effect amounts of white and gray matter as well as relative positioning and shapes of local brain anatomy. State-of-the-art morphometry meth ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health